Loading clinical trials...

Stem Cell Therapy in Limb Girdle Muscular Dystrophy | Clinical Trials | Clareo Health

WITHDRAWNPHASE1

Stem Cell Therapy in Limb Girdle Muscular Dystrophy

The Role of Cell Therapy in Modifying the Course of Limb Girdle Muscular Dystrophy- A Longitudinal 5-year Study

NCT02050776•Neurogen Brain and Spine Institute

Summary

The purpose of this study was to study the effect of stem cell therapy on the course of the disease in patients with Limb Girdle Muscular Dystrophy.

Eligibility

Age

15 - 60 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•males and females
•age group of 15 years and above
•limb girdle muscular dystrophy diagnosed on the basis of clinical presentation
•Electromyographic and Nerve Conduction velocity findings

Exclusion Criteria

•presence of respiratory distress
•presence of acute infections such as Human Immunodeficient Virus/Hepatitis B Virus/Hepatitis C Virus
•malignancies
•acute medical conditions such as respiratory infection, fever, hemoglobin less than 8, bleeding tendency, bone marrow disorder, left ventricular ejection fraction \< 30%
•pregnancy or breastfeeding

Locations (1)

Neurogen brain and spine institute

Mumbai, Maharashtra, India

Key Dates

Start Date

December 1, 2008

Primary Completion Date

March 1, 2013

Completion Date

December 1, 2013

Last Updated

October 25, 2018

Conditions

Limb Girdle Muscular Dystrophy

Interventions

Autologous bone marrow mononuclear cell transplantation

BIOLOGICAL

A Gene Transfer Single Dose Study to Evaluate the Safety, Tolerability and Efficacy of SRP-9003 in Non-Ambulatory and Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2E/R4 (Beta-Sarcoglycan [β-SG] Deficiency)

NCT05876780

Limb Girdle Muscular Dystrophy

View study

ACTIVE_NOT_RECRUITING

3 Year Follow up on ANO5 Patients

NCT05206617

Neuromuscular DiseasesLimb Girdle Muscular Dystrophy

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 25, 2018Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Stem Cell Therapy in Limb Girdle Muscular Dystrophy

Inclusion Criteria

Exclusion Criteria

A Gene Transfer Single Dose Study to Evaluate the Safety, Tolerability and Efficacy of SRP-9003 in Non-Ambulatory and Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2E/R4 (Beta-Sarcoglycan [β-SG] Deficiency)

3 Year Follow up on ANO5 Patients

Study to Evaluate the Safety, Tolerability, and Efficacy of SRP-9004 Administered by Systemic Infusion in Limb Girdle Muscular Dystrophy Type 2D/R3 Participants in the United States

A Gene Transfer Study to Evaluate the Safety, Tolerability and Efficacy of SRP-6004 in Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2B/R2 (LGMD2B/R2, Dysferlin [DYSF] Related)

Schulze Muscular Dystrophy Ability Clinical Study

Clinical Study of AAV1-gamma-sarcoglycan Gene Therapy for Limb Girdle Muscular Dystrophy Type 2C